Clearmind Medicine Inc. announced on September 25, 2025, the successful convening of its inaugural Annual Scientific Advisory Board (SAB) meeting. This meeting brought together eight world-renowned professors and experts in psychiatry, addiction research, and metabolic disorders.
A central focus of the SAB discussions was Clearmind’s lead candidate, 5-Methoxy-2-aminoindane (MEAI), which is currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD). Discussions highlighted MEAI’s unique pharmacological profile, promising safety data, and potential advantages over emerging GLP-1 therapies.
The SAB reviewed preclinical findings, emphasizing MEAI’s potential to address AUD, obesity, metabolic syndrome, and veteran mental health challenges. Their insights will guide the company’s development strategy as it aims to deliver transformative psychedelic-derived therapies for global health challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.